tetano
Editor, Senior Moderator
PLoS One
. 2025 May 22;20(5):e0316131.
doi: 10.1371/journal.pone.0316131. eCollection 2025. Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23: Results of a pilot study in the SIREN cohort
Sarah Foulkes[SUP] 1 [/SUP], Katie Munro[SUP] 1 [/SUP], Dominic Sparkes[SUP] 1 [/SUP], Jonathan Broad[SUP] 1 [/SUP], Naomi Platt[SUP] 1 [/SUP], Anna Howells[SUP] 1 [/SUP], Omolola Akinbami[SUP] 1 [/SUP], Jameel Khawam[SUP] 1 [/SUP], Palak Joshi[SUP] 1 [/SUP], Sophie Russell[SUP] 1 [/SUP], Chris Norman[SUP] 2 [/SUP], Lesley Price[SUP] 3 [/SUP], Diane Corrigan[SUP] 4 [/SUP], Michelle Cole[SUP] 1 [/SUP], Jean Timeyin[SUP] 1 [/SUP], Louise Forster[SUP] 1 [/SUP], Katrina Slater[SUP] 1 [/SUP], Conall H Watson[SUP] 1 [/SUP], Nick Andrews[SUP] 1 [/SUP], Andre Charlett[SUP] 1 [/SUP], Ana Atti[SUP] 1 [/SUP], Jasmin Islam[SUP] 1 [/SUP], Colin S Brown[SUP] 1 [/SUP], Jonathan Turner[SUP] 1 [/SUP], Susan Hopkins[SUP] 1 [/SUP], Victoria Hall[SUP] 1 [/SUP]; SIREN study group
Affiliations
Introduction: The combination of patient illness and staff absence driven by seasonal viruses culminates in annual "winter pressures" on UK healthcare systems and has been exacerbated by COVID-19. In winter 2022/23 we introduce multiplex testing aiming to determine the incidence of SARS-CoV-2, influenza and respiratory syncytial virus (RSV) in our cohort of UK healthcare workers (HCWs).
Methods: The pilot study was conducted from 28/11/2022-31/03/2023 within the SIREN prospective cohort study. Participants completed fortnightly questionnaires, capturing symptoms and sick leave, and multiplex PCR testing for SARS-CoV-2, influenza and RSV, regardless of symptoms. PCR-positivity rates by virus were calculated over time, and viruses were compared by symptoms and severity. Self-reported symptoms and associated sick leave were described. Sick leave rates were compared by vaccination status and demographics.
Results: 5,863 participants were included, 84.6% female, 70.3% ≥ 45-years, 91.4% of White ethnicity and 82.6% in a patient facing role. PCR-positivity peaked in early December for all three viruses (4.6 positives per 100 tests (95%CI 3.5, 5.7) SARS-CoV-2, 3.9 (95%CI 2.2, 5.6) influenza, 1.4 (95%CI 0.4, 2.4) RSV), declining to <0.3/100 tests after January for influenza/RSV, and around 2.5/100 tests for SARS-CoV-2. Over one-third of all infections were asymptomatic, and symptoms were similar for all viruses. 1,368 (23.3%) participants reported taking sick leave, median 4 days (range 1-59). Rates of sick leave were higher in participants with co-morbidities, working in clinical settings, and who had not been vaccinated (COVID-19 booster or seasonal influenza vaccine) versus those who had received neither vaccine (2.04 vs 1.41 sick days/100 days, adjusted Incidence Rate Ratio 1.47 (95%CI 1.38, 1.56).
Conclusion: This pilot demonstrated the use of multiplex testing allowed better understanding of the impact of seasonal respiratory viruses and respective vaccines on the HCW workforce. This highlights the important information on asymptomatic infection and persisting levels of SARS-CoV-2 infection.
. 2025 May 22;20(5):e0316131.
doi: 10.1371/journal.pone.0316131. eCollection 2025. Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23: Results of a pilot study in the SIREN cohort
Sarah Foulkes[SUP] 1 [/SUP], Katie Munro[SUP] 1 [/SUP], Dominic Sparkes[SUP] 1 [/SUP], Jonathan Broad[SUP] 1 [/SUP], Naomi Platt[SUP] 1 [/SUP], Anna Howells[SUP] 1 [/SUP], Omolola Akinbami[SUP] 1 [/SUP], Jameel Khawam[SUP] 1 [/SUP], Palak Joshi[SUP] 1 [/SUP], Sophie Russell[SUP] 1 [/SUP], Chris Norman[SUP] 2 [/SUP], Lesley Price[SUP] 3 [/SUP], Diane Corrigan[SUP] 4 [/SUP], Michelle Cole[SUP] 1 [/SUP], Jean Timeyin[SUP] 1 [/SUP], Louise Forster[SUP] 1 [/SUP], Katrina Slater[SUP] 1 [/SUP], Conall H Watson[SUP] 1 [/SUP], Nick Andrews[SUP] 1 [/SUP], Andre Charlett[SUP] 1 [/SUP], Ana Atti[SUP] 1 [/SUP], Jasmin Islam[SUP] 1 [/SUP], Colin S Brown[SUP] 1 [/SUP], Jonathan Turner[SUP] 1 [/SUP], Susan Hopkins[SUP] 1 [/SUP], Victoria Hall[SUP] 1 [/SUP]; SIREN study group
Affiliations
- PMID: 40402987
- PMCID: PMC12097552
- DOI: 10.1371/journal.pone.0316131
Introduction: The combination of patient illness and staff absence driven by seasonal viruses culminates in annual "winter pressures" on UK healthcare systems and has been exacerbated by COVID-19. In winter 2022/23 we introduce multiplex testing aiming to determine the incidence of SARS-CoV-2, influenza and respiratory syncytial virus (RSV) in our cohort of UK healthcare workers (HCWs).
Methods: The pilot study was conducted from 28/11/2022-31/03/2023 within the SIREN prospective cohort study. Participants completed fortnightly questionnaires, capturing symptoms and sick leave, and multiplex PCR testing for SARS-CoV-2, influenza and RSV, regardless of symptoms. PCR-positivity rates by virus were calculated over time, and viruses were compared by symptoms and severity. Self-reported symptoms and associated sick leave were described. Sick leave rates were compared by vaccination status and demographics.
Results: 5,863 participants were included, 84.6% female, 70.3% ≥ 45-years, 91.4% of White ethnicity and 82.6% in a patient facing role. PCR-positivity peaked in early December for all three viruses (4.6 positives per 100 tests (95%CI 3.5, 5.7) SARS-CoV-2, 3.9 (95%CI 2.2, 5.6) influenza, 1.4 (95%CI 0.4, 2.4) RSV), declining to <0.3/100 tests after January for influenza/RSV, and around 2.5/100 tests for SARS-CoV-2. Over one-third of all infections were asymptomatic, and symptoms were similar for all viruses. 1,368 (23.3%) participants reported taking sick leave, median 4 days (range 1-59). Rates of sick leave were higher in participants with co-morbidities, working in clinical settings, and who had not been vaccinated (COVID-19 booster or seasonal influenza vaccine) versus those who had received neither vaccine (2.04 vs 1.41 sick days/100 days, adjusted Incidence Rate Ratio 1.47 (95%CI 1.38, 1.56).
Conclusion: This pilot demonstrated the use of multiplex testing allowed better understanding of the impact of seasonal respiratory viruses and respective vaccines on the HCW workforce. This highlights the important information on asymptomatic infection and persisting levels of SARS-CoV-2 infection.